These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 2172593)

  • 21. The safety of heparins in end-stage renal disease.
    Sonawane S; Kasbekar N; Berns JS
    Semin Dial; 2006; 19(4):305-10. PubMed ID: 16893408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [When lipids increase in dialysis: the role of heparin! Standard heparin increases, low-molecular-weight heparin lowers triglycerides].
    Wiemer J; Scherberich JE
    MMW Fortschr Med; 1999 Oct; 141(43):29-32. PubMed ID: 10912118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term effects of low molecular weight heparin on lipid parameters in hemodialysis patients.
    Elisaf MS; Bairaktari H; Germanos N; Pappas M; Koulouridis E; Papagalanis N; Siamopoulos KC
    Int Angiol; 1996 Sep; 15(3):252-6. PubMed ID: 8971586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Epidemiology of anticoagulation for hemodialysis patients: survey of 842 cases in seven hemodialysis centers].
    Sun XF; Xiao Q; Wang Y; Hao LR; Lin HL; Zhang ZM; Li JJ; Chen XM
    Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(9):577-81. PubMed ID: 19595154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session: the impact of the administered dose.
    Fourtounas C
    Am J Kidney Dis; 2008 Oct; 52(4):805-6; author reply 806-7. PubMed ID: 18805352
    [No Abstract]   [Full Text] [Related]  

  • 26. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
    Harenberg J; Haaf B; Dempfle CE; Stehle G; Heene DL
    Nephrol Dial Transplant; 1995; 10(2):217-22. PubMed ID: 7753456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Individual dosage schedule of heparin therapy in chronic hemodialysis by analytic studies of blood coagulation].
    Gläser V; Anstadt M
    Z Urol Nephrol; 1990 Mar; 83(3):133-40. PubMed ID: 2356667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction.
    Brophy DF; Martin EJ; Best AM; Gehr TW; Carr ME
    J Thromb Haemost; 2004 Aug; 2(8):1299-304. PubMed ID: 15304034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secreted platelet proteins with antiheparin and mitogenic activities in chronic renal failure.
    Guzzo J; Niewiarowski S; Musial J; Bastl C; Grossman RA; Rao AK; Berman I; Paul D
    J Lab Clin Med; 1980 Jul; 96(1):102-13. PubMed ID: 6446588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low molecular weight heparin in haemodialysis for chronic renal failure: dose finding study of CY222.
    Ireland H; Lane DA; Flynn A; Pegrum AC; Curtis JR
    Thromb Haemost; 1988 Apr; 59(2):240-7. PubMed ID: 2838924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis.
    Kario K; Matsuo T; Yamada T; Matsuo M
    Thromb Haemost; 1994 Mar; 71(3):275-9. PubMed ID: 8029788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unfractionated heparin but not enoxaparin causes delayed plasma PAI-1 depletion in hemodialysis patients: a prospective study.
    Naumnik B; Pawlak K; Mys'liwiec M
    Clin Appl Thromb Hemost; 2009 Feb; 15(1):84-91. PubMed ID: 17895513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Haemostasis parameters behaviour during haemodialysis without anticoagulants.
    Casati S; Moia M; Graziani G; Cantaluppi A; Mannucci PM; Ponticelli C
    Life Support Syst; 1983; 1 Suppl 1():144-7. PubMed ID: 6336396
    [No Abstract]   [Full Text] [Related]  

  • 34. About the effect of low-molecular-weight heparin on platelet function in haemodialysis patients.
    Eleftheriadis T; Antoniadi G; Liakopoulos V; Stefanidis I
    Nephrol Dial Transplant; 2009 Mar; 24(3):1063-4. PubMed ID: 19131348
    [No Abstract]   [Full Text] [Related]  

  • 35. Adjusting the dose of low molecular weight heparins in renally impaired and obese patients.
    Spinler S
    Clin Adv Hematol Oncol; 2004 May; 2(5):270, 273-4. PubMed ID: 16163192
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session.
    Brunet P; Simon N; Opris A; Faure V; Lorec-Penet AM; Portugal H; Dussol B; Berland Y
    Am J Kidney Dis; 2008 May; 51(5):789-95. PubMed ID: 18436089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-molecular-weight heparin (LMWH): influence on blood lipids in patients on chronic haemodialysis.
    Schmitt Y; Schneider H
    Nephrol Dial Transplant; 1993; 8(5):438-42. PubMed ID: 8393549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A contribution safety on using low molecular weight heparin in patients with renal failure].
    Gea Rodríguez E; Barral Viñals N; Manso Mardones P; Indo Berges O
    Farm Hosp; 2004; 28(2):101-5. PubMed ID: 15101801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The use of enoxaparine for anticoagulation in extracorporeal circulation in hemodialysis at high risk for hemorrhage].
    Dechelette E; Pouzol P; Jurkovitz C; Kuentz F; Polack B; Cuzin E; Woler M
    J Mal Vasc; 1987; 12 Suppl B():105-7. PubMed ID: 2834479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retroperitoneal hematoma in a hemodialysis patient receiving low molecular weight heparin.
    Kruzel-Davila E; Frajewicki V; Kushnir D; Eyal A; Kohan R
    Isr Med Assoc J; 2005 Sep; 7(9):611-2. PubMed ID: 16190491
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.